Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents

European Journal of Medicinal Chemistry

Volumn 87, Issue , 2014, Pages 814-833

  Asati, Vivek ^a   Mahapatra, Debarshi Kar ^a   Bharti, Sanjay K ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Antiproliferative activity; ERK; Kinases; PI3K; Signaling pathways; Thiazolidine 2,4 dione

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMSACRINE; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYGLUCOSE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; HYDANTOIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PODOPHYLLOTOXIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RESVERATROL; RHODANINE; ROSIGLITAZONE; TROGLITAZONE; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CYTOTOXICITY; DERIVATIZATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IC50; IN VITRO STUDY; MEDICINAL CHEMISTRY; MOLECULAR DOCKING; PROTEIN PHOSPHORYLATION; RAJI CELL LINE; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84908053507     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.025     Document Type: Short Survey

References (99)

1. Cancer Facts & Figures 2013 American Cancer Society http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
2. Globocan 2012 IARC
3. R.A. Smith V. Cokkinides O.W. Brawley Cancer J. Clin. 59 2009 27 41
4. J.C. Reed Apoptosis-based therapies Nat. Rev. Drug Discov. 1 2002 111 121
5. J.C. Reed M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood 106 2005 408 418
6. Q.P. Peterson D.C. Hsu D.R. Goode C.J. Novotny R.K. Totten P.J. Hergenrother Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular colocalization with caspase-3 J. Med. Chem. 52 2009 5721 5731
7. S.X. Cai B. Nguyen S. Jia J. Herich J. Guastella S. Reddy B. Tseng J. Drewe S. Kasibhatla Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell-and caspase-based high throughput screening assay J. Med. Chem. 46 2003 2474 2481
8. A. Nefzi J.M. Ostresh R.A. Houghten Chem. Rev. 97 1997 449
9. M. Yu M. Tsuyoshi Y. Tohru K. Mitsuru O. Hiroyuki I. Hitoshi S. Takashi Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers and anti-diabetic activities J. Med. Chem. 45 2002 1518 1534
10. C.D. Barros A.A. Amato T.B. Oliveira K.B.R. Iannini A.L. Silva T.G. Silva E.S. Leite M.Z. Hernandes M.C.A. Lima S.L. Galdino F.A.R. Neves I.R. Pitta Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-dione as PPAR ligands Bioorg. Med. Chem. 18 2010 3805 3811
11. N. Swathi Y. Ramu C.V.S. Subrahmanyam K. Satyanarayana Synthesis, quantum mechanical calculation and biological evaluation of 5-(4-substituted aryl/hetero aryl methylidene)-1,3-thiazolidine-2,4-diones Int. J. Pharm. Sci. 4 2012 561 566
12. S.R. Pattan K.R. Alagwadi A.R. Bhat V.V.K. Reddy J.S. Pattan A.B. Khade K.G. Bhatt Synthesis and evaluation of some 5-[1-{4-4-substituted phenyl amino}-meth-(Z)-ylidene]-thiazolidine-2,4-dione for antitubercular activity Indian Drugs 45 2008 532 535
13. B. Oya O. Ozen M. Arzu K. Engin E. Rahmiye Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4-dione derivatives Bioorg. Med. Chem. 15 2007 6012 6017
14. S.A.H. El-Feky Synthesis and anticonvulsant properties of some novel quinazolinone thiazolidine and 4-thiazolidone derivatives Pharmazie 48 1993 894 896
15. G.A. Shankar R.A. Kallanagouda New thiazolidinedione-5-acetic acid amide derivatives: synthesis, characterization and investigation of antimicrobial and cytotoxic properties Med. Chem. Res. 21 2012 816 824
16. B. Meunier Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 41 2008 69 77
17. L. Xu J. Vagner J. Josan R.M. Lynch D.L. Morse B. Baggett H. Han E.A. Mash V.J. Hruby J. Robert Enhanced targeting with heterobivalent ligands Mol. Cancer Ther. 8 8 2009 2356 2365
18. K. Liu W. Rao H. Parikh Q. Li T.L. Guo S. Grant G.E. Kellogg S. Zhang 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization Eur. J. Med. Chem. 47 2012 125 137
19. A.G. Smith K.A. Beaumont E.O. Muscat Int. J. Biochem. Cell Biol. 41 2009 844 852
20. T. Yoshizumi T. Ohta I. Ninomiya I. Terada S. Fushida T. Fujimura G.I. Nishimura K. Shimizu S. Yi K. Miwa Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects Int. J. Oncol. 25 3 2004 631
21. L. Michalik J. Auwerx J.P. Berger V.K. Chatterjee C.K. Glass F.J. Gonzalez P.A. Grimaldi T. Kadowaki M.A. Lazar S. O'Rahilly C.N. Palmer J. Plutzky J.K. Reddy B.M. Spiegelman B. Staels W. Wahli Peroxisome proliferator-activated receptors Pharmacol. Rev. 58 4 2006 726 741
22. P.J. Lapinskas J.C. Corton Molecular mechanisms of hepatocarcinogenic peroxisome proliferators A. Puga K.B. Wallace Molecular Biology of the Toxic Response 1998 Taylor & Francis Philadelphia 219 253
23. K. Yu W. Bayona C.B. Kallen H.P. Harding C.P. Ravera G. McMahon M. Brown M.A. Lazar Differential activation of peroxisome proliferator-activated receptors by eicosanoids J. Biol. Chem. 270 1995 23975 23983
24. A. Belfiore M. Genua R. Malaguarnera PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer PPAR Res. 2009 2009 830501
25. J. Berger D.E. Moller The mechanisms of action of PPARs Annu. Rev. Med. 53 2002 409 435
26. J.N. Feige L. Gelman L. Michalik B. Desvergne W. Wahli From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions Prog. Lipid Res. 45 2 2006 120 159
27. S. Sikka L. Chen G. Sethi A.P. Kumar Targeting PPARγ signaling cascade for the prevention and treatment of prostate cancer PPAR Res. 2012 2012 968040
28. M.J. Kim D. Deplewski N. Ciletti S. Michel U. Reichert R.L. Rosenfield Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development Mol. Genet. Metab. 74 2001 362 369
29. A. Ijpenberg E. Jeannin W. Wahli B. Desvergne Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA: a functional analysis of the malic enzyme gene PPAR response element J. Biol. Chem. 272 1997 20108 20117
30. W. Wahli O. Braissant B. Desvergne Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more Chem. Biol. 2 1995 261 266
31. S.A. Kliewer B.M. Forman B. Blumberg E.S. Ong U. Borgmeyer D.J. Mangelsdorf Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proc. Natl. Acad. Sci. 91 1994 7355 7359
32. J.M. Lehmann L.B. Moore T.A. Smith-Oliver W.O. Wilkison T.M. Willson S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
33. T. Osumi J.K. Wen T. Hashimoto Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene Biochem. Biophys. Res. Commun. 175 1991 866 871
34. P. Tontonoz E. Hu R.A. Graves A.I. Budavari B.M. Spiegelman mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer Genes Dev. 8 1994 1224 1234
35. J. Bar-Tana Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans Toxicol. Lett. 120 2001 9 19
36. S. Green W. Wahli Peroxisome proliferator-activated receptors: finding the orphan a home Mol. Cell. Endocrinol. 100 1994 149 153
37. M. Wang S. Tafuri Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis J. Cell. Biochem. 89 2003 38 47
38. V. Chandra P. Huang Y. Hamuro S. Raghuram Y. Wang T.P. Burris F. Rastinejad Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA Nature 2008 350 356
39. P.D. Gregory K. Wagner W. Hörz Histone acetylation and chromatin remodeling Exp. Cell Res. 265 2 2001 195 202
40. P. Gervois I.P. Torra J.C. Fruchart B. Staels Regulation of lipid and lipoprotein metabolism by PPAR activators Clin. Chem. Lab. Med. 38 1 2000 3 11
41. P.R. Devchand H. Keller J.M. Peters M. Vazquez F.J. Gonzalez W. Wahli The PPARa-leukotriene B4 pathway to inflammation control Nature 384 1996 39 43
42. B. Staels K. Wolfgang A. Habib R. Merval M. Lebret I.P. Torra P. Delerive A. Fadel G. Chinetti J.C. Fruchart J. Najib J. Maclouf A. Tedgui Activation of human aortic smooth-muscle cells is inhibited by PPARα but not PPARγ activators Nature 393 1998 790 793
43. H. Lim R.A. Gupta W. Ma B.C. Paria D.E. Moller J.D. Morrow R.N. DuBois J.M. Trzaskos S.K. Dey Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARd Genes Dev. 13 1999 561 574
44. Y. Zhu C. Qi J.R. Korenberg X.N. Chen D. Noya M.S. Rao J.K. Reddy Structural organization of mouse peroxisome proliferatoractivated receptor gamma (mPPAR) gamma gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms Proc. Natl. Acad. Sci. 92 1995 7921 7925
45. B. Soret H.J. Lee E. Finley S.C. Lee R.G. Vernon Regulation of differentiation of sheep subcutaneous and abdominal preadipocytes in culture J. Endocrinol. 161 1999 517 524
46. C. Fontaine G. Dubois Y. Duguay T. Helledie N. Vu-Dac P. Gervois F. Soncin S. Mandrup J.C. Fruchart J. Fruchart-Najib B. Staels The orphan nuclear receptor Rev-Erbb is a peroxisome proliferator-activated receptor (PPAR)-g target gene and promotes PPAR-γ-induced adipocyte differentiation J. Biol. Chem. 278 2003 37672 37680
47. E. Mueller P. Sarraf P. Tontonoz R.M. Evans K.J. Martin M. Zhang C. Fletcher S. Singer B.M. Spiegelman Terminal differentiation of human breast cancer through PPAR-γ Mol. Cell 1 1998 465 470
48. C.D. Allred M.W. Kilogore Selective activation of PPARgamma in breast, colon, and lung cancer cell lines Mol. Cell. Endocrinol. 235 2005 21 29
49. S. Nomura A. Nakajima S. Ishimine N. Matsuhashi T. Kadowaki M. Kaminishi Differential expression of peroxisome proliferatoractivated receptor in histologically different human gastric cancer tissues J. Exp. Clin. Cancer Res. 25 2006 443 448
50. R.M. Cesario J. Stone W.C. Yen R.P. Bissonnette W.W. Lamph Differentiation and growth inhibition mediated via the RXR: PPARgamma heterodimer in colon cancer Cancer Lett. 240 2006 225 233
51. G. Kristiansen J. Jacob A.C. Buckendahl R. Grutzmann M. Dietel C. Pilarsky Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times Clin. Cancer Res. 12 2006 6444 6451
52. W. Motomura N. Takahashi M. Nagamine M. Sawamukai S. Tanno Y. Kohgo T. Okimura Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells Int. J. Cancer 108 2004 41 46
53. S. Han N. Sidell P.B. Fisher J. Roman Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells Clin. Cancer Res. 10 2004 1911 1919
54. S.K. Radhakrishnan A. Gartel The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines Cell Cycle 4 2005 582 584
55. D. Fujii K. Yoshida K. Tanabe J. Hihara T. Toge The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest Anticancer Res. 24 2004 1409 1416
56. C. Blanquicett J. Roman C.M. Hart Thiazolidinediones as anti-cancer agents Cancer Ther. 6 A 2008 25 34
57. H. Sato S. Ishihara K. Kawashima N. Moriyama H. Suetsugu H. Kazumori T. Okuyama M.A. Rumi R. Fukuda N. Nagasue Y. Kinoshita Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists Br. J. Cancer 83 2000 1394 1400
58. T. Takashima Y. Fujiwara K. Higuchi T. Arakawa Y. Yano T. Hasuma S. Otani PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity Int. J. Oncol. 19 2001 465 471
59. J. Lu K. Imamura S. Nomura K. Mafune A. Nakajima T. Kadowaki N. Kubota Y. Terauchi G. Ishii A. Ochiai H. Esumi M. Kaminishi Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice Cancer Res. 65 2005 4769 4774
60. F.S. Chou P.S. Wang S. Kulp Joseph J. Pinzone Effects of thiazolidinediones on differentiation, proliferation, and apoptosis Mol. Cancer Res. 5 6 2007 523 530
61. H. Joshi T. Pal C. Ramaa A new dawn for the use of thiazolidinediones in cancer therapy Expert Opin. Investig. Drugs 23 4 2014 501 510
62. B. Grygiel-Górniak Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications Nutr. J. 13 1 2014 17
63. Z. Yan Z. Zhu J. Wang J. Sun Y. Chen G. Yang W. Chen Y. Deng Synthesis, characterization, and evaluation of a novel inhibitor of WNT/β-catenin signaling pathway Mol. Cancer 12 2013 116
64. J. Mao S. Fan W. Ma P. Fan B. Wang J. Zhang H. Wang B. Tang Q. Zhang X. Yu L. Wang B. Song L. Li Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment Cell Death Dis. 5 2014 e1039
65. H.H. Luu R. Zhang R.C. Haydon E. Rayburn Q. Kang W. Si J.K. Park H. Wang Y. Peng W. Jiang T.C. He Wnt/beta-catenin signaling pathway as a novel cancer drug target Curr. Cancer Drug Targets 4 8 2004 653 671
66. J. Liu X. Dai Y. Xu P. Liu Y. Zhang X. Liu Z. Fang D. Lin R. Xiao R. Huang Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-γ ligands via Wnt signaling pathway Cell Biochem. Biophys. 62 1 2012 19 27
67. B. Zhou S.T. Buckley V. Patel Y. Liu J. Luo M.S. Krishnaveni M. Ivan L. DeMaio K.J. Kim C. Ehrhardt E.D. Crandall Z. Borok Troglitazone attenuates TGF-β1-induced EMT in alveolar epithelial cells via a PPARγ-independent mechanism PLoS One 7 6 2012 e38827
68. P.S. Wang F.S. Chou M. Bloomston M.S. Vonau M. Saji A. Espinosa J.J. Pinzone Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells J. Surg. Res. 153 2 2009 210 216
69. R.A. Hilger M.E. Scheulen D. Strumberg The Ras-Raf-MEK-ERK pathway in the treatment of cancer Onkologie 25 2002 511 518
70. M.H. Cobb MAP kinase pathways Prog. Biophys. Mol. Biol. 71 1999 479 500
71. K.S. Smalley A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer 104 2003 527 532
72. C. Rommel B.A. Clarke S. Zimmermann L. Nunez R. Rossman K. Reid K. Moelling G.D. Yancopoulos D.J. Glass Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt Science 286 1999 1738
73. F. Chang L.S. Steelman J.T. Lee J.G. Shelton P.M. Navolanic W.L. Blalock R.A. Franklin J.A. McCubrey Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention Leukemia 17 2003 1263 1293
74. I. Grillier-Vuissoz S. Mazerbourg M. Boisbrun S. Kuntz Y. Chapleur S. Flament PPARγ-independent activity of thiazolidinediones: a promising mechanism of action for new anticancer drugs? J. Carcinog. Mutagen. 2012 2157 2518 S8-002
75. Y. Fukunaga H. Itoh K. Doi T. Tanaka J. Yamashita T.H. Chun M. Inoue K. Masatsugu N. Sawada T. Saito K. Hosoda H. Kook M. Ueda K. Nakao Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides Atherosclerosis 158 1 2001 113 119
76. S. Wei S.K. Kulp C.S. Chen Energy restriction as an antitumor target of thiazolidinediones J. Biol. Chem. 285 13 2010 9780 9791
77. R. Romagnoli P.G. Baraldi M.K. Salvador M.E. Camacho J. Balzarini J. Bermejo F. Estévez Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione Eur. J. Med. Chem. 63 2013 544 557
78. S.H. Kim Y.J. Choi K.M. Moon H.J. Lee Y. Wooc K.W. Chung Y. Jung S. Kim P. Chun Y. Byun Y.M. Ha H.R. Moon H.Y. Chung The inhibitory effect of a synthetic compound, (Z)-5-(2,4-dihydroxybenzylidene) thiazolidine-2,4-dione (MHY498), on nitric oxide-induced melanogenesis Bioorg. Med. Chem. Lett. 23 2013 4332 4335
79. M. Azizmohammadi M. Khoobi A. Ramazani S. Emami A. Zarrin O. Firuzi R. Miri A. Shafiee 2H-Chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents Eur. J. Med. Chem. 59 2013 15 22
80. J. Park T.S. Morley P.E. Scherer Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours EMBO Mol. Med. 5 6 2013 935 948
81. T.C. Chen D.S. Yu K.F. Huang Y.C. Fu C.C. Lee C.L. Chen F.C. Huang H.H. Hsieh J.J. Lin H.S. Huang Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents Eur. J. Med. Chem. 69 2013 278 293
82. C.C. Lee K.F. Huang D.M. Chang J.J. Hsu F.C. Huang K.N. Shih C.L. Chen T.C. Chen R.H. Chen J.J. Lin H.S. Huang Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones Eur. J. Med. Chem. 50 2012 102 112
83. D. Havrylyuk B. Zimenkovsky O. Vasylenko C.W. Day D.F. Smee P. Grellier R. Lesyk Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones Eur. J. Med. Chem. 66 2013 228 237
84. S.K. Suthar V. Jaiswal S. Lohan S. Bansal A. Chaudhary A. Tiwari A.T. Alex A. Joesph Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: design, synthesis and biological screening Eur. J. Med. Chem. 63 2013 589 602
85. R. Mohan A.K. Sharma S. Gupta C.S. Ramaa Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line Med. Chem. Res. 21 2012 1156 1165
86. Q. Li A. Al-Ayoubi T. Guo H. Zheng A. Sarkar T. Nguyen S.T. Eblen S. Grant G.E. Kellogg S. Zhang Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxybenzylidene)-thiazolidine-2,4-dione: development of potential substratespecific ERK1/2 inhibitors Bioorg. Med. Chem. Lett. 19 2009 6042 6046
87. W. Motomura S. Tanno N. Takahashi M. Nagamine M. Fukuda Y. Kohgo T. Okumura Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells Biochem. Biophys. Res. Commun. 332 1 2005 89 94
88. A. Sugimura Y. Kiriyama H. Nochi H. Tsuchiya K. Tamoto Y. Sakurada M. Ui Y. Tokumitsu Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor Biochem. Biophys. Res. Commun. 261 3 1999 833 837
89. Q. Li J. Wua H. Zheng K. Liu T.L. Guo Y. Liu S.T. Eblen S. Grant S. Zhang Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways Bioorg. Med. Chem. Lett. 20 2010 4526 4530
90. H. Chen Y.H. Fan A. Natarajan Y. Guo J. Iyasere F. Harbinski L. Luus W. Christ H. Aktasa J.A. Halperin Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation Bioorg. Med. Chem. Lett. 14 2004 5401 5405
91. B.N. Meyer N.R. Ferrigni J.E. Putnam L.B. Jacobsen D.E. Nichols J.L. McLaughlin Planta Med. 45 1982 31
92. V.R. Avupati R.P. Yejella A. Akula G.S. Guntuku B.R. Doddi V.R. Vutla S.R. Anagani L.S. Adimulam A.K. Vyricharla Synthesis, characterization and biological evaluation of some novel 2,4 thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents Bioorg. Med. Chem. Lett. 22 2012 6442 6450
93. L. Nagarapu B. Yadagiri R. Bantu C.G. Kumar S. Pombala J. Nanubolu Studies on the synthetic and structural aspects of benzosuberones bearing 2, 4-thiazolidenone moiety as potential anti-cancer agents Eur. J. Med. Chem. 71 2014 91 97
94. M. Ferreira L.S. Assunção F.B. Filippin-Monteiro T.B. Creczynski-Pasa M.M. Sa Synthesis of 1,3-thiazine-2,4-diones with potential anticancer activity Eur. J. Med. Chem. 70 2013 411 418
95. F.W.A. Barros T.G. Silva M.G.R. Pitta D.P. Bezerra L.V. Costa-Lotufo M.O. de Moraes C. Pessoa M.A.F.B. de Moura F.C. de Abreu M.C.A. de Lima S.L. Galdino I.R. Pitta M.O.F. Goulart Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives Bioorg. Med. Chem. 20 2013 3533 3539
96. P.A. Datar, S.B. Aher. Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents, http://dx.doi.org/10.1016/j.jscs.2012.10.010.
97. L.A. Dakin M.H. Block H. Chen E. Code J.E. Dowling X. Feng A.D. Ferguson I. Green A.W. Hird T. Howard E.K. Keeton M.L. Lamb P.D. Lyne H. Pollard J. Read A.J. Wu T. Zhang X. Zheng Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases Bioorg. Med. Chem. Lett. 22 2012 4599 4604
98. Y.M. Ha Y.J. Park J.A. Kim D. Park J.Y. Park H.J. Lee J.Y. Lee H.R. Moon H.Y. Chung Design and synthesis of 5-(substituted benzylidene)thiazolidine-2,4-dione derivatives as novel tyrosinase inhibitors Eur. J. Med. Chem. 49 2012 245 252
99. F. Sandrine D. Catherine V. Karina R. Caroline L. Stéphanie L. Nathalie B. Carlo D. Samuel B. Nicoletta M. Giorgio A. Jean-Pierre S. Paul R. Eric Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer 24 2006 25 35